Elan Antegren Strategy: Separate Crohn’s Maintenance And Induction Claims
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Elan/Biogen Idec’s regulatory strategy for gaining approval of Antegren (natalizumab) for Crohn’s disease appears to be centered on separating indications for induction and maintenance therapy.